英文药名：IMUNACE Injection（Teceleukin(Genetical recombination)）

中文药名：替西白介素基因重组注射剂

生产厂家：盐野义制药

イムネース注35

治疗类别名称
重组白细胞介素-2制剂
商標名
Imunace35
一般的名称：
テセロイキン（遺伝子組換え）（JAN）［日局］
Teceleukin（Genetical Recombination）
略号：
rIL-2
分子式：
C698H1127N179O204S8
分子量：
15547.01
化学構造式：
它是由134个氨基酸的多肽组成
　
性状：
它是无色透明的液体
适应病症
1.血管肉瘤
2.肾细胞癌
用法用量
1. 血管肉瘤
溶解于生理盐水溶液或5％葡萄糖注射液等，通常情况下，70万单位每天静脉内输注分为一到两次。
此外，年龄，将根据症状最大剂量被调整为1天140万单位。
2.肾细胞癌
溶解于生理盐水溶液或5％葡萄糖注射液等，通常情况下，70万单位每天静脉内输注分为一到两次。
此外，年龄，将根据症状最大剂量被调整为1天210万单位。
通过升高，肝功能检查异常，因为体液潴留倾向于表达，应注意。
注意事项：
注射液的制备方法
1.每瓶（Teseroikin35万单位），注射用水1mL中加入并溶解该附件。
2.除在200〜500毫升，例如生理盐水溶液或5％葡萄糖注射液为静脉内输注的单剂量。
药效药理
1.药理作用
(1) 抗肿瘤作用（in vitro）
健康成人6名患者（5名男性患者，女一例）时培养72小时，加入70单位/ mL在从获得的外周血淋巴细胞，诱导对人肾癌细胞培养物3应变强烈的细胞毒活性这是。然而，它并没有显示在正常细胞（ConA刺激人正常淋巴细胞）的任何影响。
(2) 抗肿瘤作用（in vivo）
对于RENCA（自发小鼠肾癌），它表现出的存活的延长，转移抑制效果。
也表现出对化学致癌的小鼠肾脏癌症的显著转变的抑制作用。
2. 作用机序
主要结合到T细胞和NK细胞，通过激活，通过诱导的故障的肿瘤细胞毒性能力高的杀伤细胞。另外还结合B细胞和巨噬细胞，刺激免疫。
包装规格
注：35万单位 1瓶（附加注射用水1mL中）

制造厂商
盐野义制药有限公司

IMUNACE35 for Injection（イムネース注35）
Brand name: IMUNACE35 for Injection
　Active ingredient: Teceleukin (Genetical recombination)
　Dosage form: injection
　Print on wrapping: 
Effects of this medicine
This medicine improves immunity by activating lymphocytes, and it damages cancer cells via immune reactions. Furthermore, it shows an inhibitory effect against metastasis of cancer.
It is usually used for the treatment of angiosarcoma and kidney cancer.
Before using this medicine, be sure to tell your doctor and pharmacist
•If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines and vaccines.
•If you are pregnant or breastfeeding.
•If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)
Dosing schedule (How to take this medicine)
•Your dosing schedule prescribed by your doctor is <<to be written by a healthcare professional>>
•In general, for adults, this medicine is administered by intravenous drip infusion daily in 1 to 2 divided doses on consecutive days.
•The schedule for use is determined according to your symptoms. Consult with your doctor about your concrete schedule for use.
Precautions while taking this medicine
•If you are breastfeeding, avoid breastfeeding while using this medicine.
Possible adverse reactions to this medicine
The most commonly reported adverse reactions include fever, chill, shiver, malaise, loss of appetite, nausea, vomiting, headache, diarrhea, weight gain, edema, water retention, decreased urine output, retention of pleural effusion (dry cough, breathlessness, chest pain), breathing difficulty, deperession, hypotension, irregular heartbeat, palpitation, frequent pulse and cold sense in lower limbs. If any of these symptoms occur, consult with your doctor or pharmacist.
The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately.
•weight gain, swelling, decreased urine output  [retention of body fluid]
•swelling, shortness of breath, cough  [congestive heart failure]
•feeling depressed and unmotivated, sleeplessness, malaise, suicide attempt  [depression, suicide attempt]
•infection by bacteria, fever, cough  [(in case of using a large amount of it) induced infection, exacerbation of infection]
•malaise, yellowness in skin and in the white of eyes, thirstiness, increased urine output  [autoimmune phenomenon]
The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.
Shionogi & Co., Ltd.Injection
Published: 2/2014
The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment.